We describe a case of dose-related periorbital edema in a patient with FLT3-mutated acute myeloid leukemia taking sorafenib and voriconazole that resolved following sorafenib dose reduction. We hypothesize that the mechanism of this adverse event may be related to the inhibition of platelet-derived growth factor receptor (PDGFR) by sorafenib. Clinicians should be aware of this possible dose-related adverse event and the potential role of sorafenib dose reduction when on concurrent voriconazole.
MetzelderSKSchroederTFinckA, et al.High activity of sorafenib in FLT3-ITD-positive acute myeloid leukemia synergizes with allo-immune effects to induce sustained responses. Leukemia2012; 26: 2353–2359.
2.
RavandiFAlattarMLGrunwaldMR, et al.Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation. Blood2013; 121: 4655–4662.
3.
UyGLMandrekarSJLaumannK, et al.A phase 2 study incorporating sorafenib into the chemotherapy for older adults with FLT3-mutated acute myeloid leukemia: CALGB 11001. Blood Adv2017; 1: 331–340.
AutierJEscudierBWechslerJ, et al.Prospective study of the cutaneous adverse effects of sorafenib, a novel multikinase inhibitor. Arch Dermatol2008; 144: 886–892.
6.
RobertCSoriaJCSpatzA, et al.Cutaneous side-effects of kinase inhibitors and blocking antibodies. Lancet Oncol2005; 6: 491–500.
BlockMSKohliM. Clinical hypothyroidism in a renal cell carcinoma patient treated with sorafenib. Clin Adv Hematol Oncol2011; 9: 335–338.
9.
LathiaCLettieriJCihonF, et al.Lack of effect of ketoconazole-mediated CYP3A inhibition on sorafenib clinical pharmacokinetics. Cancer Chemother Pharmacol2006; 57: 685–692.
10.
NaranjoCABustoUSellersEM, et al.A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther1981; 30: 239–245.
